Friday, 13 Jul 2018

You are here

Less Cardiovascular Risk with Abatacept in Rheumatoid Arthritis

A claims data analysis shows that abatacept use in rheumatoid arthritis (RA) patients yielded a modestly reduced cardiovascular risk when compared to patients receiving TNF inhibitors (TNFi).

Using claims data from Medicare and MarketScan, researchers from Harvard assessed the frequency of cardiovascular (CV) outcomes in RA patients receiving either ABA or TNFi.  The primary outcome was a composite cardiovascular end point of myocardial infarction (MI), stroke/transient ischemic attack, and coronary revascularization.

The study included 13 039 PS‐matched patients on either abatacept (ABA) or TNFi.  Background diabetes (DM) was found 34.7% of Medicare and 19.8% of MarketScan patients.

CV events were less frequent with abatacept use versus TNF inhibitor; the HR was 0.81 (0.66–0.99) in Medicare and 0.95 (0.74–1.23) in MarketScan, with a pooled HR of 0.86 (95% CI, 0.73–1.01; P=0.3 for heterogeneity).

While those with diabetes had an even lower CV event rate for ABA vs. TNFi (HR 0.74; 95%CI 0.57–0.96; P=0.7) for heterogeneity), the same was not seen in those without diabetes  (pooled HR 0.94; 95% CI, 0.77–1.14; P=0.4).

In RA patients, ABA was be associated with a modest reduction in cardiovascular risk (compared with TNFi), particularly in patients with DM.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Defining Refractory RA by Biologic Use

A study from the  British Society for Rheumatology Biologics Register (BSRBR) has shown that biologic refractory disease is seen in at least 6% of patients who have ever received a biologic DMARD (bDMARDs).

IL-23 Inhibitor Fails in Ankylosing Spondylitis

A study of the IL-23 risankizumab in active ankylosing spondylitis (AS) patients failed to show efficacy and did not meet primary efficacy endpoints in a 6-month trial.

Five Barriers to Biosimilar Adoption in the US

A recent Deloitte analysis of the biosimilar market in the USA suggests there are defined obstacles to biosimilar use that must be dealt with, especially as the current administration is seeking to lower drug prices and reduce out-of-pocket costs for US consumers.

EULAR 2018 - Day 4 Report

The EULAR 2018 wound down on Saturday with fewer oral presentations but many posters.  In my last report I put together a collection of impressions and some thematic highlights not covered in previous reports. Also some of these represent research and reporting trends – some healthy, others not so – that were evident at the EULAR 2018 meeting.

Pain 

High Biologic Blood Levels Increases the Risk of Infections in RA

A big concern of most is the risk of infection with use of tumour necrosis factor inhibitor (TNFi) and biologic drugs.  While studied in both trials and in post-marketing studies, it is unknown if infection risk is dose-dependent.

In abstract OP0229 UK researchers have shown high biologic blood levels are associates with an increased risk of total infections in RA, but not serious infetions.